Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2007

Open Access 01-12-2007 | Research article

TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study

Authors: David Bacman, Susanne Merkel, Roland Croner, Thomas Papadopoulos, Wolfgang Brueckl, Arno Dimmler

Published in: BMC Cancer | Issue 1/2007

Login to get access

Abstract

Background

Histological phenotype and clinical behaviour of malignant tumours are not only dependent on alterations in the epithelial cell compartment, but are affected by their interaction with inflammatory cells and tumour-associated stroma. Studies in animal models have shown influence of tumour-associated macrophages (TAM) on histological grade of differentiation in colon carcinoma. Disruption of transforming growth factor beta (TGF-beta) signalling in tumour cells is related to more aggressive clinical behaviour. Expression data of components of this pathway in tumour-associated stroma is limited.

Methods

Tissue micro arrays of 310 colon carcinomas from curatively resected patients in UICC stage II and III were established. In a first step we quantified amount of CD68 positive TAMs and expression of components of TGF-beta signalling (TGF-beta1, TGF-beta receptors type 1 and 2, Smad 3 and 4) in tumour and associated stroma. Further we analyzed correlation to histological and clinical parameters (histological grade of differentiation (low-grade (i.e. grade 1 and 2) vs. high-grade (i.e. grade 3 and 4)), lymph node metastasis, distant metastasis, 5 year cancer related survival) using Chi-square or Fisher's exact test, when appropriate, to compare frequencies, Kaplan-Meier method to calculate 5-year rates of distant metastases and cancer-related survival and log rank test to compare the rates of distant metastases and survival. To identify independent prognostic factors Cox regression analysis including lymph node status and grading was performed.

Results

High-grade tumours and those with lymph node metastases showed higher rates of TAMs and lower expression of TGF-beta1. Loss of nuclear Smad4 expression in tumor was associated with presence of lymph node metastasis, but no influence on prognosis could be demonstrated. Decrease of both TGF-beta receptors in tumour-associated stroma was associated with increased lymph node metastasis and shorter survival. Stromal TGF-beta receptor 2 expression was an independent prognostic factor for cancer related survival.

Conclusion

Histological phenotype and clinical behaviour of colon cancer is not only influenced by mutational incidents in tumour cells but also affected by interaction of tumour tissue with inflammatory cells like macrophages and associated stroma and TGF-beta signalling is one important part of this crosstalk. Further studies are needed to elucidate the exact mechanisms.
Appendix
Available only for authorised users
Literature
1.
Balkwill F, Mantovani A: Inflammation and cancer: back to Virchow?. Lancet. 2001, 357 (9255): 539-545. 10.1016/S0140-6736(00)04046-0.CrossRefPubMed
2.
3.
Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL: Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 1996, 56 (20): 4625-4629.PubMed
4.
Bingle L, Brown NJ, Lewis CE: The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002, 196 (3): 254-265. 10.1002/path.1027.CrossRefPubMed
5.
6.
Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L: The origin and function of tumor-associated macrophages. Immunol Today. 1992, 13 (7): 265-270. 10.1016/0167-5699(92)90008-U.CrossRefPubMed
7.
Ohno S, Inagawa H, Dhar DK, Fujii T, Ueda S, Tachibana M, Suzuki N, Inoue M, Soma G, Nagasue N: The degree of macrophage infiltration into the cancer cell nest is a significant predictor of survival in gastric cancer patients. Anticancer Res. 2003, 23 (6D): 5015-5022.PubMed
8.
Kataki A, Scheid P, Piet M, Marie B, Martinet N, Martinet Y, Vignaud JM: Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression. J Lab Clin Med. 2002, 140 (5): 320-328. 10.1067/mlc.2002.128317.CrossRefPubMed
9.
Nakayama Y, Nagashima N, Minagawa N, Inoue Y, Katsuki T, Onitsuka K, Sako T, Hirata K, Nagata N, Itoh H: Relationships between tumor-associated macrophages and clinicopathological factors in patients with colorectal cancer. Anticancer Res. 2002, 22 (6C): 4291-4296.PubMed
10.
Roberts AB, Anzano MA, Wakefield LM, Roche NS, Stern DF, Sporn MB: Type beta transforming growth factor: a bifunctional regulator of cellular growth. Proc Natl Acad Sci U S A. 1985, 82 (1): 119-123. 10.1073/pnas.82.1.119.CrossRefPubMedPubMedCentral
11.
Massague J: TGF-beta signal transduction. Annu Rev Biochem. 1998, 67: 753-791. 10.1146/annurev.biochem.67.1.753.CrossRefPubMed
12.
Derynck R, Feng XH: TGF-beta receptor signaling. Biochim Biophys Acta. 1997, 1333 (2): F105-50.PubMed
13.
Ko TC, Beauchamp RD, Townsend CM, Thompson EA, Thompson JC: Transforming growth factor-beta inhibits rat intestinal cell growth by regulating cell cycle specific gene expression. Am J Surg. 1994, 167 (1): 14-9; discussion 19-20. 10.1016/0002-9610(94)90048-5.CrossRefPubMed
14.
Ko TC, Sheng HM, Reisman D, Thompson EA, Beauchamp RD: Transforming growth factor-beta 1 inhibits cyclin D1 expression in intestinal epithelial cells. Oncogene. 1995, 10 (1): 177-184.PubMed
15.
Conery AR, Cao Y, Thompson EA, Townsend CM, Ko TC, Luo K: Akt interacts directly with Smad3 to regulate the sensitivity to TGF-beta induced apoptosis. Nat Cell Biol. 2004, 6 (4): 366-372. 10.1038/ncb1117.CrossRefPubMed
16.
Derynck R, Akhurst RJ, Balmain A: TGF-beta signaling in tumor suppression and cancer progression. Nat Genet. 2001, 29 (2): 117-129. 10.1038/ng1001-117.CrossRefPubMed
17.
Akhurst RJ, Derynck R: TGF-beta signaling in cancer--a double-edged sword. Trends Cell Biol. 2001, 11 (11): S44-51. 10.1016/S0962-8924(01)02130-4.CrossRefPubMed
18.
Robson H, Anderson E, James RD, Schofield PF: Transforming growth factor beta 1 expression in human colorectal tumours: an independent prognostic marker in a subgroup of poor prognosis patients. Br J Cancer. 1996, 74 (5): 753-758.CrossRefPubMedPubMedCentral
19.
Friedman E, Gold LI, Klimstra D, Zeng ZS, Winawer S, Cohen A: High levels of transforming growth factor beta 1 correlate with disease progression in human colon cancer. Cancer Epidemiol Biomarkers Prev. 1995, 4 (5): 549-554.PubMed
20.
Wang J, Han W, Zborowska E, Liang J, Wang X, Willson JK, Sun L, Brattain MG: Reduced expression of transforming growth factor beta type I receptor contributes to the malignancy of human colon carcinoma cells. J Biol Chem. 1996, 271 (29): 17366-17371. 10.1074/jbc.271.29.17366.CrossRefPubMed
21.
Matsushita M, Matsuzaki K, Date M, Watanabe T, Shibano K, Nakagawa T, Yanagitani S, Amoh Y, Takemoto H, Ogata N, Yamamoto C, Kubota Y, Seki T, Inokuchi H, Nishizawa M, Takada H, Sawamura T, Okamura A, Inoue K: Down-regulation of TGF-beta receptors in human colorectal cancer: implications for cancer development. Br J Cancer. 1999, 80 (1-2): 194-205. 10.1038/sj.bjc.6690339.CrossRefPubMedPubMedCentral
22.
Riggins GJ, Thiagalingam S, Rozenblum E, Weinstein CL, Kern SE, Hamilton SR, Willson JK, Markowitz SD, Kinzler KW, Vogelstein B: Mad-related genes in the human. Nat Genet. 1996, 13 (3): 347-349. 10.1038/ng0796-347.CrossRefPubMed
23.
Eppert K, Scherer SW, Ozcelik H, Pirone R, Hoodless P, Kim H, Tsui LC, Bapat B, Gallinger S, Andrulis IL, Thomsen GH, Wrana JL, Attisano L: MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell. 1996, 86 (4): 543-552. 10.1016/S0092-8674(00)80128-2.CrossRefPubMed
24.
Thiagalingam S, Lengauer C, Leach FS, Schutte M, Hahn SA, Overhauser J, Willson JK, Markowitz S, Hamilton SR, Kern SE, Kinzler KW, Vogelstein B: Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet. 1996, 13 (3): 343-346. 10.1038/ng0796-343.CrossRefPubMed
25.
Takagi Y, Kohmura H, Futamura M, Kida H, Tanemura H, Shimokawa K, Saji S: Somatic alterations of the DPC4 gene in human colorectal cancers in vivo. Gastroenterology. 1996, 111 (5): 1369-1372. 10.1053/gast.1996.v111.pm8898652.CrossRefPubMed
26.
MacGrogan D, Pegram M, Slamon D, Bookstein R: Comparative mutational analysis of DPC4 (Smad4) in prostatic and colorectal carcinomas. Oncogene. 1997, 15 (9): 1111-1114. 10.1038/sj.onc.1201232.CrossRefPubMed
27.
Gordon S: Alternative activation of macrophages. Nat Rev Immunol. 2003, 3 (1): 23-35. 10.1038/nri978.CrossRefPubMed
28.
Mantovani A, Sozzani S, Locati M, Allavena P, Sica A: Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002, 23 (11): 549-555. 10.1016/S1471-4906(02)02302-5.CrossRefPubMed
29.
Crowther M, Brown NJ, Bishop ET, Lewis CE: Microenvironmental influence on macrophage regulation of angiogenesis in wounds and malignant tumors. J Leukoc Biol. 2001, 70 (4): 478-490.PubMed
30.
Pollard JW: Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004, 4 (1): 71-78. 10.1038/nrc1256.CrossRefPubMed
31.
Nesbit M, Schaider H, Miller TH, Herlyn M: Low-level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumor formation in nontumorigenic melanoma cells. J Immunol. 2001, 166 (11): 6483-6490.CrossRefPubMed
32.
Dinapoli MR, Calderon CL, Lopez DM: The altered tumoricidal capacity of macrophages isolated from tumor-bearing mice is related to reduce expression of the inducible nitric oxide synthase gene. J Exp Med. 1996, 183 (4): 1323-1329. 10.1084/jem.183.4.1323.CrossRefPubMed
33.
Oosterling SJ, van der Bij GJ, Meijer GA, Tuk CW, van Garderen E, van Rooijen N, Meijer S, van der Sijp JR, Beelen RH, van Egmond M: Macrophages direct tumour histology and clinical outcome in a colon cancer model. J Pathol. 2005, 207 (2): 147-155. 10.1002/path.1830.CrossRefPubMed
34.
Tsamandas AC, Kardamakis D, Ravazoula P, Zolota V, Salakou S, Tepetes K, Kalogeropoulou C, Tsota I, Kourelis T, Makatsoris T, Karavias D, Scopa CD, Bonikos DS, Kalofonos HP, Petsas T: The potential role of TGFbeta1, TGFbeta2 and TGFbeta3 protein expression in colorectal carcinomas. Correlation with classic histopathologic factors and patient survival. Strahlenther Onkol. 2004, 180 (4): 201-208. 10.1007/s00066-004-1149-x.CrossRefPubMed
35.
Guzinska-Ustymowicz K, Kemona A: Transforming growth factor beta can be a parameter of aggressiveness of pT1 colorectal cancer. World J Gastroenterol. 2005, 11 (8): 1193-1195.CrossRefPubMedPubMedCentral
36.
Bellone G, Carbone A, Tibaudi D, Mauri F, Ferrero I, Smirne C, Suman F, Rivetti C, Migliaretti G, Camandona M, Palestro G, Emanuelli G, Rodeck U: Differential expression of transforming growth factors-beta1, -beta2 and -beta3 in human colon carcinoma. Eur J Cancer. 2001, 37 (2): 224-233. 10.1016/S0959-8049(00)00391-9.CrossRefPubMed
37.
Kouraklis G, Kakisis J, Theoharis S, Tzonou A, Glinavou A, Raftopoulos J, Karatzas G: Prognostic significance and correlation with survival of bcl-2 and TGF-beta RII in colon cancer. Dig Dis Sci. 2003, 48 (12): 2284-2289. 10.1023/B:DDAS.0000007864.24866.77.CrossRefPubMed
38.
Schwarte-Waldhoff I, Schmiegel W: Smad4 transcriptional pathways and angiogenesis. Int J Gastrointest Cancer. 2002, 31 (1-3): 47-59. 10.1385/IJGC:31:1-3:47.CrossRefPubMed
39.
Tang Y, Katuri V, Srinivasan R, Fogt F, Redman R, Anand G, Said A, Fishbein T, Zasloff M, Reddy EP, Mishra B, Mishra L: Transforming growth factor-beta suppresses nonmetastatic colon cancer through Smad4 and adaptor protein ELF at an early stage of tumorigenesis. Cancer Res. 2005, 65 (10): 4228-4237. 10.1158/0008-5472.CAN-04-4585.CrossRefPubMed
40.
Isaksson-Mettavainio M, Palmqvist R, Forssell J, Stenling R, Oberg A: SMAD4/DPC4 expression and prognosis in human colorectal cancer. Anticancer Res. 2006, 26 (1B): 507-510.PubMed
41.
Xie W, Rimm DL, Lin Y, Shih WJ, Reiss M: Loss of Smad signaling in human colorectal cancer is associated with advanced disease and poor prognosis. Cancer J. 2003, 9 (4): 302-312.CrossRefPubMed
42.
Alazzouzi H, Alhopuro P, Salovaara R, Sammalkorpi H, Jarvinen H, Mecklin JP, Hemminki A, Schwartz S, Aaltonen LA, Arango D: SMAD4 as a prognostic marker in colorectal cancer. Clin Cancer Res. 2005, 11 (7): 2606-2611. 10.1158/1078-0432.CCR-04-1458.CrossRefPubMed
43.
Maitra A, Molberg K, Albores-Saavedra J, Lindberg G: Loss of Dpc4 expression in colonic adenocarcinomas correlates with the presence of metastatic disease. Am J Pathol. 2000, 157 (4): 1105-1111.CrossRefPubMedPubMedCentral
44.
Kouvidou C, Latoufis C, Lianou E, Kouvatseas G, Kakouri E, Anagnostakis D, Vrettou-Aravani V, Betsi E, Karatapanis S: Expression of Smad4 and TGF-beta2 in colorectal carcinoma. Anticancer Res. 2006, 26 (4B): 2901-2907.PubMed
45.
Deacu E, Mori Y, Sato F, Yin J, Olaru A, Sterian A, Xu Y, Wang S, Schulmann K, Berki A, Kan T, Abraham JM, Meltzer SJ: Activin type II receptor restoration in ACVR2-deficient colon cancer cells induces transforming growth factor-beta response pathway genes. Cancer Res. 2004, 64 (21): 7690-7696. 10.1158/0008-5472.CAN-04-2082.CrossRefPubMed
46.
De Wever O, Mareel M: Role of tissue stroma in cancer cell invasion. J Pathol. 2003, 200 (4): 429-447. 10.1002/path.1398.CrossRefPubMed
47.
Michor F, Nowak MA, Iwasa Y: Evolution of resistance to cancer therapy. Curr Pharm Des. 2006, 12 (3): 261-271. 10.2174/138161206775201956.CrossRefPubMed
Metadata
Title
TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study
Authors
David Bacman
Susanne Merkel
Roland Croner
Thomas Papadopoulos
Wolfgang Brueckl
Arno Dimmler
Publication date
01-12-2007
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2007
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-7-156

Other articles of this Issue 1/2007

BMC Cancer 1/2007 Go to the issue

Research article

Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study

Study protocol

Primary resection versus neoadjuvant chemoradiation followed by resection for locally resectable or potentially resectable pancreatic carcinoma without distant metastasis. A multi-centre prospectively randomised phase II-study of the Interdisciplinary Working Group Gastrointestinal Tumours (AIO, ARO, and CAO)

Research article

Biological characterization of two xenografts derived from human CUPs (carcinomas of unknown primary)

Research article

Intratumoral delivery of IL-18 naked DNA induces T-cell activation and Th1 response in a mouse hepatic cancer model

Review

Radiotherapeutic alternatives for previously irradiated recurrent gliomas

Research article

Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits